OCT obtained authorizations for four international studies and, along with Quintiles and INC, is now ahead of PSI and Parexel by the number of obtained approvals. As of now, these five companies are the most active CROs in the period.
According to the Ministry of Health, 226 clinical trials were approved in Q2 2016, which is 16% higher than the same period last year. It is worth noting that the number of international multicenter trials also showed a significant increase, by 24%.
OCT is the market leading full-service CRO operating in Russia, Ukraine, Belarus, Bulgaria, Latvia, Lithuania, Estonia, Georgia, and the USA since 2005. OCT staff accounts for 150 professionals located in all countries of our presence. With more than 200 projects performed to date, we have solid experience across all clinical research phases and majority of indications. Find out more about our experience.